DUBLIN–(BUSINESS WIRE)–The “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.
This “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Cannabis-Induced psychosis (CIP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cannabis-Induced psychosis (CIP) Understanding
The Cannabis-Induced psychosis (CIP) epidemiology report gives a thorough understanding of the Cannabis-Induced psychosis (CIP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cannabis-Induced psychosis (CIP) in the US, Europe, and Japan. The report covers the detailed information of the Cannabis-Induced psychosis (CIP) epidemiology scenario in seven major countries (US, EU5, and Japan).
Cannabis-Induced psychosis (CIP) Epidemiology Perspective
The Cannabis-Induced psychosis (CIP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cannabis-Induced psychosis (CIP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
The Cannabis-Induced psychosis (CIP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Cannabis-Induced psychosis (CIP) Detailed Epidemiology Segmentation
The Cannabis-Induced psychosis (CIP) epidemiology covered in the report provides historical as well as forecasted Cannabis-Induced psychosis (CIP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The Cannabis-Induced psychosis (CIP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Report Highlights
- 11-year Forecast of Cannabis-Induced psychosis (CIP) epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Cannabis-Induced psychosis (CIP)
- Cases of Cannabis-Induced psychosis (CIP) by Mutation Types
- Cannabis-Induced psychosis (CIP) Cases associated with Clinical Manifestations
Key Assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Key Topics Covered:
1. Key Insights
2. Executive Summary of Cannabis-Induced psychosis (CIP)
3. Cannabis-Induced psychosis (CIP): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the 7MM (2019-2032)
5.4. United States Epidemiology
5.4.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the United States (2019-2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.2. France Epidemiology
5.5.3. Italy Epidemiology
5.5.4. Spain Epidemiology
5.5.5. United Kingdom Epidemiology
5.6. Japan Epidemiology
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Cannabis-Induced psychosis (CIP) Treatment and Management
6.2. Cannabis-Induced psychosis (CIP) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/73t5zp
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900